Emgality (galcanezumab)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- galcanezumab
- Company
- Eli Lilly Nederland B.V.
- Status
- Authorised
- Therapeutic area
- Migraine Disorders
- CHMP opinion
- Thu 20 Sep 2018
- EU approval
- Wed 14 Nov 2018
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004648
- ATC
- N02
- Official record
- www.ema.europa.eu
Indication
Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
Regulatory milestones
No milestones recorded in the last year.
Follow Emgality
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.